For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.

Just click here now to watch my presentation for free.

BOLD Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 5.30%

Insider Buying (Last 12 Months): $8,200,000.00

Insider Selling (Last 12 Months): $0.00

Audentes Therapeutics Insider Trading History Chart

Audentes Therapeutics Share Price & Price History

^$9.35

▲ +0.3 (3.31%)

As of 05/3/2024 01:00 AM ET

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad

Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…

Click For My #1 FREE Crypto for 2024

Audentes Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/2/2024	Kristina Burow	Director	Buy	200,000	$16.00	$3,200,000.00	1,181,766
4/2/2024	Ra Capital Management, L.P.	Major Shareholder	Buy	312,500	$16.00	$5,000,000.00	1,884,787

The Gold Grab of the Century

From Colonial Metals | Ad

When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

SEC Filings (Institutional Ownership Changes) for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Today's Range

Now: $9.35

$8.53

$9.42

50 Day Range

MA: $59.97

$59.97

52 Week Range

Now: $9.35

$22.00

$60.00

Volume

108,102 shs

Average Volume

110,343 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Audentes Therapeutics?: Audentes Therapeutics' top insider shareholders include:
Ra Capital Management, LP (Major Shareholder)
Kristina Burow (Director)
Learn More about top insider investors at Audentes Therapeutics.

Automatic Income (from home)

From Awesomely, LLC | Ad